Literature DB >> 29165087

Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.

Ashley D Holec1, Subhra Mandal2, Pavan Kumar Prathipati2, Christopher J Destache2.   

Abstract

BACKGROUND: Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately 658,507 lives in the US between the years 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection.
OBJECTIVE: Among various Food and Drug Administration (FDA)-approved ARVs, nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs) are most effective in limiting HIV-1 infection. This review focuses on NRTIs mechanism of action and metabolism.
METHODS: A search of PubMed (1982-2016) was performed to capture relevant articles regarding NRTI pharmacology.
RESULTS: The current classical NRTIs pharmacology for HIV-1 prevention and treatment are presented. Finally, various novel strategies are proposed to improve the efficacy of NRTIs, which will increase therapeutic efficiency of present-day HIV-1 prevention/treatment regimen.
CONCLUSION: Use of NRTIs will continue to be critical for successful treatment and prevention of HIV-1. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  AIDS; Antiretroviral drugs; HIV-1; NRTIs; antiretroviral therapy; nanomedicine

Mesh：

Substances：

Year:  2017        PMID： 29165087      PMCID： PMC7219633          DOI： 10.2174/1570162X15666171120110145

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN： 1570-162X            Impact factor:   1.581


  78 in total

1.  Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.

Authors:  Xin Wang; Tatsuhiko Furukawa; Takao Nitanda; Mika Okamoto; Yoshikazu Sugimoto; Shin-Ichi Akiyama; Masanori Baba
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

2.  Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.

Authors:  Johanna Weiss; Johanna Rose; Caroline Henrike Storch; Nahal Ketabi-Kiyanvash; Alexandra Sauer; Walter Emil Haefeli; Thomas Efferth
Journal:  J Antimicrob Chemother       Date:  2007-01-03       Impact factor: 5.790

3.  1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Authors:  S M Daluge; S S Good; M B Faletto; W H Miller; M H St Clair; L R Boone; M Tisdale; N R Parry; J E Reardon; R E Dornsife; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.

Authors:  Akil Jackson; Graeme Moyle; Victoria Watson; John Tjia; Alieu Ammara; David Back; Malika Mohabeer; Brian Gazzard; Marta Boffito
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

Review 5.  Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.

Authors:  D S Stein; K H Moore
Journal:  Pharmacotherapy       Date:  2001-01       Impact factor: 4.705

6.  3'-Deoxythymidin-2'-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion.

Authors:  E M August; E M Birks; W H Prusoff
Journal:  Mol Pharmacol       Date:  1991-02       Impact factor: 4.436

7.  Membrane permeation characteristics of abacavir in human erythrocytes and human T-lymphoblastoid CD4+ CEM cells: comparison with (-)-carbovir.

Authors:  William B Mahony; Barbara A Domin; Susan M Daluge; Thomas P Zimmerman
Journal:  Biochem Pharmacol       Date:  2004-11-01       Impact factor: 5.858

8.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

Authors:  W Y Gao; T Shirasaka; D G Johns; S Broder; H Mitsuya
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors.

Authors:  Rujuta A Bam; Gabriel Birkus; Darius Babusis; Tomas Cihlar; Stephen R Yant
Journal:  Antivir Ther       Date:  2014-03-14

10.  Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase.

Authors:  Joy Y Feng; Eisuke Murakami; Suzana M Zorca; Allison A Johnson; Kenneth A Johnson; Raymond F Schinazi; Phillip A Furman; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  14 in total

1.  Structural investigation of 2-naphthyl phenyl ether inhibitors bound to WT and Y181C reverse transcriptase highlights key features of the NNRTI binding site.

Authors:  Vincent N Duong; Joseph A Ippolito; Albert H Chan; Won-Gil Lee; Krasimir A Spasov; William L Jorgensen; Karen S Anderson
Journal:  Protein Sci       Date:  2020-08-05       Impact factor: 6.725

2.  A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.

Authors:  Subhra Mandal; Pavan Kumar Prathipati; Shawnalyn W Sunagawa; Christopher J Destache
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.938

Review 3.  The Impact of HIV- and ART-Induced Mitochondrial Dysfunction in Cellular Senescence and Aging.

Authors:  Madison Schank; Juan Zhao; Jonathan P Moorman; Zhi Q Yao
Journal:  Cells       Date:  2021-01-16       Impact factor: 6.600

4.  Retrovirus Drugs-Loaded PEGylated PAMAM for Prolonging Drug Release and Enhancing Efficiency in HIV Treatment.

Authors:  Thi Thinh Nguyen; Bao Phu Nguyen; Dinh Tien Dung Nguyen; Ngoc Hoi Nguyen; Dai Hai Nguyen; Cuu Khoa Nguyen
Journal:  Polymers (Basel)       Date:  2021-12-29       Impact factor: 4.329

Review 5.  Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.

Authors:  Zaikuan J Yu; Eric P Mosher; Namandjé N Bumpus
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-09-22       Impact factor: 13.820

6.  Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1H-pyrazole-5-carboxylate as an HIV-1 replication inhibitor.

Authors:  Jeanne Fichez; Cathia Soulie; Laurent Le Corre; Sophie Sayon; Stéphane Priet; Karine Alvarez; Olivier Delelis; Patrick Gizzi; Guillaume Prestat; Christine Gravier-Pelletier; Anne-Geneviève Marcelin; Vincent Calvez; Patricia Busca
Journal:  RSC Med Chem       Date:  2020-04-27

Review 7.  Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition.

Authors:  Yen-Ting Lai
Journal:  Viruses       Date:  2021-05-06       Impact factor: 5.048

8.  A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.

Authors:  Randolph P Matthews; Deanne Jackson Rudd; Kerry L Fillgrove; Saijuan Zhang; Charles Tomek; S Aubrey Stoch; Marian Iwamoto
Journal:  Clin Drug Investig       Date:  2021-06-21       Impact factor: 2.859

9.  A Clinical Metabolite of Azidothymidine Inhibits Experimental Choroidal Neovascularization and Retinal Pigmented Epithelium Degeneration.

Authors:  Siddharth Narendran; Felipe Pereira; Praveen Yerramothu; Ivana Apicella; Shao-Bin Wang; Akhil Varshney; Kirstie L Baker; Kenneth M Marion; Meenakshi Ambati; Vidya L Ambati; Kameshwari Ambati; Srinivas R Sadda; Bradley D Gelfand; Jayakrishna Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-08-03       Impact factor: 4.799

10.  Mechanisms of telomerase inhibition by oxidized and therapeutic dNTPs.

Authors:  Samantha L Sanford; Griffin A Welfer; Bret D Freudenthal; Patricia L Opresko
Journal:  Nat Commun       Date:  2020-10-20       Impact factor: 17.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.